The world's second largest pharmaceutical company, Glaxo-SmithKline (GSK), is planning to set up a vaccine research and development center in Taiwan, sources from the Executive Yuan said yesterday.
Russell Greig, president of GSK Pharmaceuticals International, paid a courtesy visit to Premier Yu Shyi-kun Tuesday for talks on the company's plans to establish a vaccine R&D center in Taiwan, which would be the company's first in Asia, as well as a vaccine mass production center, Executive Yuan officials said.
GSK is a world-leading research-based pharmaceutical company headquartered in the UK, with operations based in the US.
Its management signed a cooperation memorandum with Health Minister Chen Chien-jen (
Huge market
According to Greig, GSK is eyeing Asia's potentially huge market for vaccines against communicable diseases, with China as the prime target.
If the GSK vaccine R&D center is established in Taiwan, it will serve as the company's vaccine supply hub in Asia, fully dealing with demand in the region, Greig said during his meeting with Premier Yu.
Greig is expected to exchange views with Taiwan officials on two major issues: namely whether the company's branch office can establish a GSK research and development center in Taiwan, and how GSK products will be exported to China from Taiwan, according to Executive Yuan officials.
According to the nation's law, a branch office of a foreign company cannot invest in Taiwan to set up a research and development center like the one that GSK envisages establishing.
However, the GSK can easily do so if it first establishes a new company in Taiwan, the officials said
WTO solution
As to the issue of how GSK products will be exported to China from Taiwan, the officials said that as both Taiwan and China are WTO members, this will not be a problem.
In response, the government will facilitate the GSK investment plan by offering tax breaks and assistance in land acquisition, as well as by rewording relevant medical regulations and removing other investment barriers.
GSK has about a 7-percent share of the world's pharmaceutical market. It also has leadership in four major therapeutic areas -- namely anti-infective, central nervous system, respiratory, and gastro-intestinal/metabolic drugs.
GSK had sales of US$31.8 billion and before-tax profits of US$9.7 billion for last year. Pharmaceutical sales amounted to US$27 billion for last year, with new products representing 27 percent of total sales.
JITTERS: Nexperia has a 20 percent market share for chips powering simpler features such as window controls, and changing supply chains could take years European carmakers are looking into ways to scratch components made with parts from China, spooked by deepening geopolitical spats playing out through chipmaker Nexperia BV and Beijing’s export controls on rare earths. To protect operations from trade ructions, several automakers are pushing major suppliers to find permanent alternatives to Chinese semiconductors, people familiar with the matter said. The industry is considering broader changes to its supply chain to adapt to shifting geopolitics, Europe’s main suppliers lobby CLEPA head Matthias Zink said. “We had some indications already — questions like: ‘How can you supply me without this dependency on China?’” Zink, who also
At least US$50 million for the freedom of an Emirati sheikh: That is the king’s ransom paid two weeks ago to militants linked to al-Qaeda who are pushing to topple the Malian government and impose Islamic law. Alongside a crippling fuel blockade, the Group for the Support of Islam and Muslims (JNIM) has made kidnapping wealthy foreigners for a ransom a pillar of its strategy of “economic jihad.” Its goal: Oust the junta, which has struggled to contain Mali’s decade-long insurgency since taking power following back-to-back coups in 2020 and 2021, by scaring away investors and paralyzing the west African country’s economy.
BUST FEARS: While a KMT legislator asked if an AI bubble could affect Taiwan, the DGBAS minister said the sector appears on track to continue growing The local property market has cooled down moderately following a series of credit control measures designed to contain speculation, the central bank said yesterday, while remaining tight-lipped about potential rule relaxations. Lawmakers in a meeting of the legislature’s Finance Committee voiced concerns to central bank officials that the credit control measures have adversely affected the government’s tax income and small and medium-sized property developers, with limited positive effects. Housing prices have been climbing since 2016, even when the central bank imposed its first set of control measures in 2020, Chinese Nationalist Party (KMT) Legislator Lo Ting-wei (羅廷瑋) said. “Since the second half of
AI BOOST: Next year, the cloud and networking product business is expected to remain a key revenue pillar for the company, Hon Hai chairman Young Liu said Manufacturing giant Hon Hai Precision Industry Co (鴻海精密) yesterday posted its best third-quarter profit in the company’s history, backed by strong demand for artificial intelligence (AI) servers. Net profit expanded 17 percent annually to NT$57.67 billion (US$1.86 billion) from NT$44.36 billion, the company said. On a quarterly basis, net profit soared 30 percent from NT$44.36 billion, it said. Hon Hai, which is Apple Inc’s primary iPhone assembler and makes servers powered by Nvidia Corp’s AI accelerators, said earnings per share expanded to NT$4.15 from NT$3.55 a year earlier and NT$3.19 in the second quarter. Gross margin improved to 6.35 percent,
RSS